Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Atreca, Inc.
  6. News
  7. Summary
    BCEL   US04965G1094

ATRECA, INC.

(BCEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Closing Slightly Higher

07/29/2021 | 04:06pm EDT


ę MT Newswires 2021
All news about ATRECA, INC.
09/08Atreca to Present at Upcoming Virtual Investor Conferences
GL
08/11ATRECA : Reports Second Quarter 2021 Financial Results and Recent Corporate Developments (..
PU
08/11ATRECA, INC. : Results of Operations and Financial Condition, Financial Statements and Exh..
AQ
08/11Atreca Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
GL
08/11Atreca, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter a..
CI
08/11ATRECA : Management's Discussion and Analysis of Financial Condition and Results of Operat..
AQ
08/04Atreca to Present at Upcoming Virtual Investor Conferences
GL
07/30ATRECA : Wedbush Adjusts Atreca's Price Target to $12 From $27; Outperform Rating Kept
MT
07/29SECTOR UPDATE : Health Care Stocks Closing Slightly Higher
MT
07/29ATRECA : Sinks to Record Low After Early Data Shows Limited Efficacy for ATRC-101 Cancer D..
MT
More news
Analyst Recommendations on ATRECA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -109 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,28x
Yield 2021 -
Capitalization 246 M 246 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 139
Free-Float 78,5%
Chart ATRECA, INC.
Duration : Period :
Atreca, Inc. Technical Analysis Chart | BCEL | US04965G1094 | MarketScreener
Technical analysis trends ATRECA, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 6,67 $
Average target price 21,67 $
Spread / Average Target 225%
EPS Revisions
Managers and Directors
John A. Orwin President, Chief Executive Officer & Director
Herbert C. Cross Chief Financial Officer
Brian G. Atwood Chairman
Daniel Emerling Senior Vice President-Research
Wayne Volkmuth SVP-Informatics & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ATRECA, INC.-58.70%246
GILEAD SCIENCES, INC.22.52%89 497
BIONTECH SE316.17%81 938
WUXI APPTEC CO., LTD.36.63%69 841
REGENERON PHARMACEUTICALS33.94%67 273
VERTEX PHARMACEUTICALS-22.03%47 805